lubiprostone has been researched along with Cystic Fibrosis in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (44.44) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hawkins, CE; Henderson, MJ; MacDonald, KD; McKenzie, KR; Vij, N; Zeitlin, PL | 1 |
Cuthbert, AW; Joo, NS; Wine, JJ | 1 |
Kapoor, S | 1 |
Anderson, PJ; O'Brien, CE; Stowe, CD | 2 |
De Lisle, RC; Mueller, R; Roach, E | 1 |
Cuthbert, AW | 1 |
Kang, PW; Kovbasnjuk, O; Lee, S; Schiffhauer, ES; Vij, N; Walker, D; Zeitlin, PL | 1 |
Cope, G; Cuthbert, AW; MacVinish, LJ; Ropenga, A | 1 |
1 trial(s) available for lubiprostone and Cystic Fibrosis
Article | Year |
---|---|
Lubiprostone for constipation in adults with cystic fibrosis: a pilot study.
Topics: Adult; Alprostadil; Chloride Channels; CLC-2 Chloride Channels; Constipation; Cystic Fibrosis; Female; Humans; Lubiprostone; Male; Pilot Projects; Treatment Outcome; Young Adult | 2011 |
8 other study(ies) available for lubiprostone and Cystic Fibrosis
Article | Year |
---|---|
Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice.
Topics: Adenosine Triphosphate; Administration, Topical; Alprostadil; Animals; Biological Transport; Chloride Channels; Chlorides; CLC-2 Chloride Channels; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dose-Response Relationship, Drug; Electric Conductivity; Epithelium; Gene Expression Regulation; Lubiprostone; Membrane Potentials; Mice; Mice, Knockout; Respiratory System; RNA, Messenger; Subcellular Fractions | 2008 |
Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans.
Topics: Alprostadil; Animals; Anions; Carbachol; Chloride Channels; Cystic Fibrosis; Dose-Response Relationship, Drug; Electric Conductivity; Exocrine Glands; Humans; In Vitro Techniques; Lubiprostone; Mucous Membrane; Muscle Contraction; Sheep; Sus scrofa; Trachea | 2009 |
Lubiprostone: clinical applications beyond constipation.
Topics: Alprostadil; Animals; Chloride Channels; Constipation; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Laxatives; Lubiprostone; Muscle Contraction | 2009 |
Use of the chloride channel activator lubiprostone for constipation in adults with cystic fibrosis: a case series.
Topics: Adult; Alprostadil; Chloride Channels; Constipation; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Intestinal Obstruction; Lubiprostone; Male; Secondary Prevention; Treatment Outcome; Young Adult | 2010 |
Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.
Topics: Alprostadil; Animals; Bacteria; Bacterial Load; Chloride Channels; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Animal; Immunity, Innate; Intestine, Small; Lubiprostone; Mice; Mice, Inbred C57BL; Phenotype | 2010 |
Lubiprostone targets prostanoid EPâ‚„ receptors in ovine airways.
Topics: Adenylyl Cyclases; Alprostadil; Animals; Chloride Channels; CLC-2 Chloride Channels; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Cells; Humans; Lubiprostone; Molecular Targeted Therapy; Receptors, Prostaglandin E, EP4 Subtype; Respiratory Mucosa; Sheep; Thiophenes; Trachea; Triazoles | 2011 |
Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelia.
Topics: Alprostadil; Animals; Chloride Channels; CLC-2 Chloride Channels; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genotype; Ion Transport; Lubiprostone; Membrane Potentials; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nasal Mucosa; Scorpion Venoms | 2013 |
Chloride transporting capability of Calu-3 epithelia following persistent knockdown of the cystic fibrosis transmembrane conductance regulator, CFTR.
Topics: Adenylyl Cyclases; Alprostadil; Carbachol; Cell Line; Chloride Channels; Chlorides; CLC-2 Chloride Channels; Colforsin; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dose-Response Relationship, Drug; Enzyme Activation; Epithelial Cells; Fatty Acids; Genetic Vectors; Humans; Lubiprostone; Lung; Membrane Potentials; Muscarinic Agonists; Retroviridae; RNA Interference; RNA, Small Interfering; Time Factors | 2007 |